MI-2 (CAS: 1047953-91-2) is a potent MALT1 inhibitor with an IC50 of 5.84 μM. It binds directly to MALT1 and irreversibly blocks its protease activity. This leads to the suppression of NF-κB reporter activity, inhibits c-REL nuclear localization, and downregulates NF-κB target genes. Additionally, MI-2 shows no toxicity in animal studies, making it a useful research tool.
Key Applications of MI-2:
- Cancer Research:
MI-2 targets MALT1, which is essential for the survival of lymphoma cells. By inhibiting MALT1, it helps explore treatment strategies for B-cell lymphomas and MALT lymphomas. - Autoimmune Disease Studies:
MI-2 effectively suppresses the NF-κB pathway, a key player in immune response. It is used to investigate potential treatments for autoimmune diseases. - NF-κB Pathway Studies:
MI-2 blocks NF-κB activation by inhibiting MALT1, reducing c-REL nuclear translocation and gene expression. This provides insights into controlling inflammation and immune responses.
Conclusion:
MI-2 is a powerful tool in cancer and immune research. Its ability to inhibit MALT1 and its non-toxic profile in animals make it valuable for developing therapies for lymphomas and autoimmune diseases through the NF-κB pathway.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
